Epidemiology of chronic obstructive pulmonary disease in Brazil: a systematic review and meta-analysis

Cruz, Marina; Santos, Marcos André Moura dos

doi:10.1183/13993003.congress-2019.pa3319

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low-and middle-income countries (LMICs) are experiencing a disproportionate increase in noncommunicable diseases (NCD), with COPD already being a serious public health issue (WHO, 2019). A recent meta-analysis by Cruz and Santos estimated the prevalence of COPD among adults aged ≥ 40 years in Brazil at 19% (CI 95% 14.0-24.0%) (Cruz and Santos, 2019).…”

Section: Introductionmentioning

confidence: 99%

Survival Analysis of COPD Patients in a 13-Year Nationwide Cohort Study of the Brazilian National Health System

et al. 2022

View full text Add to dashboard Cite

BackgroundChronic obstructive pulmonary disease (COPD) has an appreciable socioeconomical impact in low- and middle-income countries, but most epidemiological data originate from high-income countries. For this reason, it is especially important to understand survival and factors associated with survival in COPD patients in these countries.ObjectiveTo assess survival of COPD patients in Brazil, to identify risk factors associated with overall survival, including treatment options funded by the Brazilian National Health System (SUS).MethodologyWe built a retrospective cohort study of patients dispensed COPD treatment in SUS, from 2003 to 2015 using a National Database created from the record linkage of administrative databases. We further matched patients 1:1 based on sex, age and year of entry to assess the effect of the medicines on patient survival. We used the Kaplan-Meier method to estimate overall survival of patients, and Cox's model of proportional risks to assess risk factors.ResultThirty seven thousand and nine hundred and thirty eight patients were included. Patient's survival rates at 1 and 10 years were 97.6% (CI 95% 97.4–97.8) and 83.1% (CI 95% 81.9–84.3), respectively. The multivariate analysis showed that male patients, over 65 years old and underweight had an increased risk of death. Therapeutic regimens containing a bronchodilator in a free dose along with a fixed-dose combination of corticosteroid and bronchodilator seem to be a protective factor when compared to other regimens.ConclusionOur findings contribute to the knowledge of COPD patients' profile, survival rate and related risk factors, providing new evidence that supports the debate about pharmacological therapy and healthcare of these patients.

show abstract

Section: Introductionmentioning

confidence: 99%